未登录.png)
分享.png)
收藏HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial
Li, Qiao; Cheng, Ying; Tong, Zhongsheng; Liu, Yunjiang; Wang, Xian; Yan, Min; Chang, Jianhua; Wang, Shusen; Du, Caiwen; Li, Liang; Wu, Chunjiao; Wang, Mingxia; Wang, Zhuo; Wu, Zhuli; Wang, Xingli; Jin, Yongli; Diao, Lei; Sun, Yi; Zhang, Yongjiao; Hui, Ai-Min; Xu, Binghe 分享 收藏 分享 收藏 Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in ChinaAvatrombopag治疗成人慢性原发性免疫性血小板减少症: 一项在中国的随机3期试验Mei, Heng; Zhou, Hu; Hou, Ming; Sun, Jing; Zhang, Lei; Luo, Jianmin; Jiang, Zhongxing; Ye, Xu; Xu, Yajing; Lu, Jun; Wang, Hui; Hui, Aimin; Zhou, Yongchun; Hu, Yu 分享 收藏 Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromasHu, Xiaojie; Li, Wenbin; Zeng, Kang; Xu, Zhongyuan; Li, Changxing; Kang, Zhuang; Li, Shenglan; Huang, Xin; Han, Pu; Lin, Hongmei; Hui, Ai-Min; Tan, Yan; Diao, Lei; Li, Ben; Wang, Xingli; Wu, Zhuli; Lin, Xiaoxi 分享 收藏 FS-1502, an anti-HER2 ADC, in Patients with HER2-Expressing Advanced Solid Tumors: A Phase 1a Dose-Escalation StudyLi, Qiao; Wang, Xian; Cheng, Ying; Liu, Yunjiang; Chang, Jianhua; Wang, Zhuo; Wu, Chunjiao; Wang, Mingxia; Hui, Ai-Min; Wu, Zhuli; Jin, Yongli; Huang, Xin; Zhong, Liping; Diao, Lei; Zhao, Han; Xu, Binghe 分享 收藏 Phase 2 Study of the CDK4/6 Inhibitor FCN-437c in Combination With Fulvestrant or Letrozole and Goserelin in Patients With HR+, HER2-Advanced Breast CancerShi, JiaJie; Li, Wei; Tong, Zhongsheng; Zang, Aimin; Zeng, Xiaohua; Wang, Shui; Huang, Tao; Wang, Ying; Song, Yanqiu; Kang, Lihua; Lv, Zheng; Shi, Yehui; Yang, Hua; Wu, Jing; Yin, Yongmei; Liang, Yan; Tan, Jie; Ming, Jie; Yang, Yaping; Luo, Simin; Gui, Xiujuan; Hui, Ai-Min; Wu, Zhuli; Tian, Ling; Yang, Yuchen; Diao, Lei; Zhang, Wenjing; Zhang, Yongjiao; Liu, Yunjiang 分享 收藏 Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese MalesLi, Jiangfan; Tan, Yan; Li, Kexin; Hui, Ai-Min; Wu, Zhuli; Han, Pu; Wei, Zhen; Qiu, Jingjun; Diao, Lei; Wang, Xuhong 分享 收藏 Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialBNT162b2 mRNA疫苗在中国成年人中的免疫原性和安全性: 一项2期随机临床试验Hui, Ai -Min; Li, Jingxin; Zhu, Li; Tang, Rong; Ye, Huayue; Lin, Mei; Ge, Lei; Wang, Xiyuan; Peng, Fuzhong; Wu, Zhenggang; Guo, Xiling; Shi, Yunfeng; Pan, Hongxing; Zhu, Jiahong; Song, Zhizhou; Qiu, Jingjun; Wang, Wei; Zheng, Jianfei; Ozhelvaci, Orkun; Shpyro, Svetlana; Bushway, Meghan; Derhovanessian, Evelyna; Kuhnle, Marie-Cristine; Luxemburger, Ulrich; Muik, Alexander; Shishkova, Yoana; Khondker, Zakaria; Hu, Simin; Lagkadinou, Eleni; Sahin, Ugur; Tureci, Ozlem; Zhu, Fengcai 分享 收藏 A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanomaMao, Lili; Guo, Jun; Zhu, Lingjun; Jiang, Yu; Yan, Wangjun; Zhang, Jian; Hui, Ai-Min; Yang, Yuchen; Diao, Lei; Tan, Yan; Zhao, Han; Jiang, Yiqian; Wu, Zhuli; Si, Lu 分享 收藏 分享 收藏 分享 收藏 Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial中国成年人SARS-CoV-2接种BNT162b1 mRNA疫苗后的免疫持久性和安全性: 一项随机、安慰剂对照、双盲1期试验Li, Jingxin; Hui, Ai-Min; Zhang, Xiang; Ge, Lei; Qiu, Yuanzheng; Tang, Rong; Ye, Huayue; Wang, Xiyuan; Lin, Mei; Zhu, Zhongkui; Zheng, Jianfei; Qiu, Jingjun; Lagkadinou, Eleni; Shpyro, Svetlana; Ozhelvaci, Orkun; Tureci, Ozlem; Khondker, Zakaria; Yin, Wanrong; Shishkova, Yoana; Jia, Siyue; Pan, Hongxing; Peng, Fuzhong; Ma, Zhilong; Wu, Zhenggang; Guo, Xiling; Shi, Yunfeng; Muik, Alexander; Sahin, Ugur; Zhu, Li; Zhu, Fengcai 分享 收藏 分享 收藏 分享 收藏 Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 StudyCong, Duanduan; Song, Jie; Liu, Yue; Tan, Yan; Xue, Wei; Liu, Xiaohui; Qi, Wenyuan; Lu, Jun; Yuan, Xiaojuan; Zhou, Yongchun; Hui, Ai-Min; Li, Kexin 分享 收藏 分享 收藏 Phase la study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR+/HER2-advanced breast cancerZhang, Jian; Wang, Xiaojia; Wang, Xian; Hui, Aimin; Wu, Zhuli; Tian, Ling; Xu, Changjiang; Yang, Yuchen; Zhang, Wenjing; Hu, Xichun 分享 收藏 Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 studyLi, Jingxin; Hui, Aimin; Zhang, Xiang; Yang, Yumei; Tang, Rong; Ye, Huayue; Ji, Ruiru; Lin, Mei; Zhu, Zhongkui; Tureci, Ozlem; Lagkadinou, Eleni; Jia, Siyue; Pan, Hongxing; Peng, Fuzhong; Ma, Zhilong; Wu, Zhenggang; Guo, Xiling; Shi, Yunfeng; Muik, Alexander; Sahin, Ugur; Zhu, Li; Zhu, Fengcai 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
